Phase 1 study of CS-7017 in combination with FOLFIRI

ABSTRACT: Intervention name : CS-7017 INN of the intervention : efatutazone Dosage And administration of the intervention : CS-7017(0.25-0.50 mg) administered orally twice a day Control intervention name : null Primary outcome(s): Safety and Pharmacokinetics -To evaluate the safety profile according to CTCAE -To evaluate the pharmacokinetics according to the protocol Study Design: Open Label Phase 1 Study

DISEASE(S): Metastatic Crc Who Failed First-line Therapy

PROVIDER: 2610363 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR